Boston Scientific(US:BSX) ZACKSยท2025-08-07 14:01Core Viewpoint - Boston Scientific (BSX) has been a focus of investor interest, with its stock performance being influenced by various fundamental factors and earnings estimates revisions [1][2]. Earnings Estimates Revisions - For the current quarter, Boston Scientific is expected to report earnings of $0.71 per share, reflecting a year-over-year increase of +12.7% [5]. - The Zacks Consensus Estimate for the current fiscal year is $2.98, indicating a year-over-year change of +18.7% [5]. - For the next fiscal year, the consensus earnings estimate is $3.37, representing a +13.3% change from the previous year [6]. - The recent changes in earnings estimates have led to a Zacks Rank of 2 (Buy) for Boston Scientific, suggesting potential for price appreciation [7]. Revenue Growth Projections - The consensus sales estimate for the current quarter is $4.95 billion, indicating a year-over-year increase of +17.7% [11]. - For the current fiscal year, the revenue estimate is $19.8 billion, reflecting an +18.3% change, while the next fiscal year is projected at $21.99 billion, indicating an +11% change [11]. Recent Performance and Surprise History - Boston Scientific reported revenues of $5.06 billion in the last quarter, a year-over-year increase of +22.8%, and an EPS of $0.75, up from $0.62 a year ago [12]. - The company has consistently beaten consensus EPS and revenue estimates over the past four quarters [13]. Valuation Metrics - Boston Scientific has a Zacks Value Style Score of D, indicating it is trading at a premium compared to its peers [17]. - Valuation multiples such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF) are essential for assessing whether the stock is overvalued or undervalued [15][16]. Conclusion - The combination of strong earnings growth, positive revenue projections, and a favorable Zacks Rank suggests that Boston Scientific may outperform the broader market in the near term [18].